Chronic heart failure is a therapeutic problem in cardiology, a serious disease that incapacitates patients and has a high prevalence and mortality rate. According to an epidemiological survey of heart failure in 2003, the prevalence of heart failure among people aged 35-74 years was 0.9%. Based on this rate, the prevalence of heart failure in China
There are about 4 million patients with heart failure among people aged 35-74. The death rate of heart failure is related to the clinical severity. In the case of moderate to severe heart failure, the 5-year mortality rate can be 30% to 50%, and over the past decades, with angiotensin-converting enzyme inhibitors (or angiotensin receptor antagonists), β-blockers, and
However, a significant number of patients still have poor outcomes. Cardiac resynchronous pacing (CRT) has been used for more than 10 years for the treatment of heart failure. In addition to implanting electrodes in the right atrium and right ventricle, left ventricular electrodes are also implanted through the coronary vein system. Through three stages of development, CRT has now become a Class I indication for the treatment of heart failure. The indications for CRT treatment in China are recommended as follows: 1, ischemic or non-ischemic cardiomyopathy after adequate anti-cardiac failure drug therapy, cardiac function is still in class III or class IV without bed rest; 2, sinus rhythm; 3, LVEF ≤ 35%; 4, LVEDD ≥ 55 mm; 5, QRS time limit ≥ 120
ms with cardiac motion asynchrony. The key to CRT implantation is the implantation of left ventricular electrodes, and with the development of implantation devices and the accumulation of implantation experience, the success rate of CRT implantation has improved significantly.